The data summarized in this review suggest that a lipid metabolic enzyme, ACSL4, responsible for the activation of long-chain polyunsaturated fatty acids as a prerequisite to both incorporation into complex lipids as well as oxidation, functions as a biomarker for receptor negative status (QNBC) as well as for resistance to hormone-based therapies in receptor positive cancers. Here, ACSL4 is linked to cancer.